Joachim Beck

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

Ivar Bleumer, Alexander Knuth, Egbert Oosterwijk et al. · British Journal of Cancer · 2004 · 173 citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant Cisplatin Plus Methotrexate Versus Methotrexate, Vinblastine, Epirubicin, and Cisplatin in Locally Advanced Bladder Cancer: Results of a Randomized, Multicenter, Phase III Trial (AUO-AB 05/95)

Margitta Retz, Christina Wiemers, Joachim Beck et al. · Journal of Clinical Oncology · 2005 · 119 citations

Medicine, Oncology, Urology +13

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

Michael Siebels, K. Rohrmann, R. Oberneder et al. · World Journal of Urology · 2010 · 101 citations

Medicine, Oncology, Pharmacology +13

A Clinical Trial With Chimeric Monoclonal Antibody WX-G250 and Low Dose Interleukin-2 Pulsing Scheme for Advanced Renal Cell Carcinoma

Ivar Bleumer, Egbert Oosterwijk, Jeannette Oosterwijk‐Wakka et al. · The Journal of Urology · 2005 · 92 citations

Medicine, Oncology, Pharmacology +17

Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses

Rudolf Lichtenfels, Roland Kellner, Derek Atkins et al. · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · 2003 · 83 citations

Life Sciences, Biochemistry, Molecular Biology +16